Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2020 May 8

PMID 32376613

Citations 39

Authors

Laurent Softic

Rozenn Brillet

Francois Berry

Nazim Ahnou

Quentin Nevers

Margot Morin-Dewaele

Sabah Hamadat

Patrice Bruscella

Slim Fourati

Jean-Michel Pawlotsky

Abdelhakim Ahmed-Belkacem

Affiliations

Soon will be listed here.

Abstract

Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.

Citing Articles

Evaluating the potential of non-immunosuppressive cyclosporin analogs for targeting Toxoplasma gondii cyclophilin: Insights from structural studies.

Favretto F, Jimenez-Faraco E, Catucci G, Di Matteo A, Travaglini-Allocatelli C, Sadeghi S Protein Sci. 2024; 33(10):e5157.

PMID: 39312281 PMC: 11418636. DOI: 10.1002/pro.5157.

Cyclophilin inhibition as a strategy for the treatment of human disease.

Stauffer W, Goodman A, Gallay P Front Pharmacol. 2024; 15:1417945.

PMID: 39045055 PMC: 11264201. DOI: 10.3389/fphar.2024.1417945.

Taming Conformational Heterogeneity on Ion Racetrack to Unveil Principles that Drive Membrane Permeation of Cyclosporines.

Limbach M, Lindberg E, Olivos H, van Tetering L, Steren C, Martens J JACS Au. 2024; 4(4):1458-1470.

PMID: 38665661 PMC: 11040698. DOI: 10.1021/jacsau.4c00011.

Drug Repurposing: Insights into Current Advances and Future Applications.

Bhatia T, Sharma S Curr Med Chem. 2023; 32(3):468-510.

PMID: 37946344 DOI: 10.2174/0109298673266470231023110841.

Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.

Williams A, Zhan C BioDrugs. 2023; 37(5):649-674.

PMID: 37464099 DOI: 10.1007/s40259-023-00611-8.

References

Chen Z, Mi L, Xu J, Yu J, Wang X, Jiang J . Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. J Infect Dis. 2005; 191(5):755-60. PMC: 7110046. DOI: 10.1086/427811. View

Tanaka Y, Sato Y, Osawa S, Inoue M, Tanaka S, Sasaki T . Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet Res. 2012; 43:41. PMC: 3403912. DOI: 10.1186/1297-9716-43-41. View

Pawlotsky J, Flisiak R, Sarin S, Rasenack J, Piratvisuth T, Chuang W . Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015; 62(4):1013-23. DOI: 10.1002/hep.27960. View

Tanaka Y, Sato Y, Sasaki T . Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B. J Gen Virol. 2016; 98(2):190-200. PMC: 7079567. DOI: 10.1099/jgv.0.000663. View

de Wilde A, Pham U, Posthuma C, Snijder E . Cyclophilins and cyclophilin inhibitors in nidovirus replication. Virology. 2018; 522:46-55. PMC: 7112023. DOI: 10.1016/j.virol.2018.06.011. View

Luo C, Luo H, Zheng S, Gui C, Yue L, Yu C . Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem Biophys Res Commun. 2004; 321(3):557-65. PMC: 7092810. DOI: 10.1016/j.bbrc.2004.07.003. View

de Wilde A, Zevenhoven-Dobbe J, van der Meer Y, Thiel V, Narayanan K, Makino S . Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011; 92(Pt 11):2542-2548. PMC: 3352363. DOI: 10.1099/vir.0.034983-0. View

Pfefferle S, Schopf J, Kogl M, Friedel C, Muller M, Carbajo-Lozoya J . The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011; 7(10):e1002331. PMC: 3203193. DOI: 10.1371/journal.ppat.1002331. View

de Wilde A, Falzarano D, Zevenhoven-Dobbe J, Beugeling C, Fett C, Martellaro C . Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res. 2016; 228:7-13. PMC: 7114565. DOI: 10.1016/j.virusres.2016.11.011. View

10.

Ma-Lauer Y, Zheng Y, Malesevic M, von Brunn B, Fischer G, von Brunn A . Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res. 2019; 173:104620. PMC: 7114175. DOI: 10.1016/j.antiviral.2019.104620. View

11.

Carbajo-Lozoya J, Ma-Lauer Y, Malesevic M, Theuerkorn M, Kahlert V, Prell E . Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. 2014; 184:44-53. PMC: 7114444. DOI: 10.1016/j.virusres.2014.02.010. View

12.

von Brunn A, Ciesek S, von Brunn B, Carbajo-Lozoya J . Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication. Curr Opin Virol. 2015; 14:56-61. PMC: 7102849. DOI: 10.1016/j.coviro.2015.08.004. View